BIO KEY INTERNATIONAL INC (BKYI)
BIO KEY INTERNATIONAL INC (BKYI)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Bad debt expense | NaN | -15,000 | NaN | NaN |
| Deferred income tax benefit | NaN | 16,500 | NaN | NaN |
| Amortization of operating lease right-of-use assets | NaN | 12,876 | NaN | 12,543 |
| Net loss | -205,037 | -4,289,156 | -964,849 | -1,903,941 |
| Allowance for credit losses | NaN | -250,000 | NaN | NaN |
| Depreciation | 14,716 | 19,444 | 21,266 | 43,748 |
| Amortization of debt discount | NaN | 261,833 | NaN | NaN |
| Amortization of intangible assets | 56,039 | 56,206 | 56,329 | 154,738 |
| Amortization of capitalized contract costs | 40,000 | 38,848 | 42,448 | 91,766 |
| Amortization of note payable | -159,167 | NaN | 60,000 | 120,000 |
| Interest payable on note | 27,000 | -14,573 | 12,680 | 60,175 |
| Loss on foreign currency | NaN | 0 | NaN | NaN |
| Reserve for inventory | -98,970 | -513,400 | 0 | NaN |
| Impairment of investment | NaN | 2,500,000 | NaN | NaN |
| Operating leases right-of-use assets | -12,369 | NaN | 18,939 | NaN |
| Share and warrant-based compensation for employees and consultants | 40,744 | 40,586 | 31,660 | 74,325 |
| Stock based directors fees | 0 | 0 | 0 | 20,004 |
| Bad debts | -15,000 | NaN | 0 | 15,000 |
| Accounts receivable | 352,632 | 261,318 | -24,030 | 15,305 |
| Allowance for credit losses | NaN | NaN | 0 | -250,000 |
| Due from factor | 0 | 0 | -154,769 | 80,599 |
| Capitalized contract costs | 22,824 | 14,562 | 11,200 | 49,465 |
| Deposits | NaN | 0 | NaN | NaN |
| Right of use asset | NaN | 0 | NaN | NaN |
| Inventory | -131,452 | -536,697 | 75,638 | -59,769 |
| Resalable software license rights | NaN | NaN | 0 | NaN |
| Prepaid expenses and other | 74,720 | -101,052 | 49,330 | 24,397 |
| Accounts payable | 2,074 | -148,620 | -233,331 | 71,322 |
| Income tax payable | NaN | 0 | NaN | NaN |
| Accrued liabilities | -206,831 | 119,553 | 43,488 | -107,843 |
| Deferred revenue | 265,404 | -99,676 | -235,350 | 619 |
| Operating lease liabilities | -1,819 | -6,495 | -6,132 | -7,783 |
| Net cash used in operating activities | -358,001 | -1,830,601 | -1,122,764 | -1,715,324 |
| Costs incurred for issuance of common stock | NaN | 462,994 | NaN | NaN |
| Capital expenditures | 0 | 4,639 | 1,325 | 6,048 |
| Proceeds from issuance of note payable | NaN | 0 | 1,000,000 | 0 |
| Net cash used in investing activities | 0 | -4,639 | -1,325 | -6,048 |
| Offering costs | -248,783 | NaN | 0 | 248,783 |
| Proceeds from employee stock purchase plan | NaN | 9,200 | 0 | 876 |
| Repayment of note payable | NaN | 455,000 | NaN | NaN |
| Proceeds for exercise of warrants | 0 | 3,153,501 | 0 | 3,813,057 |
| Repayment of government loan | -38,179 | -37,256 | -37,492 | -71,645 |
| Net cash used in financing activities | -38,179 | 2,456,234 | 962,508 | 3,493,505 |
| Effect of exchange rate changes | -50,499 | 33,816 | -73,911 | 65,608 |
| Net increase (decrease) in cash and cash equivalents | -446,679 | 654,810 | -235,492 | 1,837,741 |
| Cash and cash equivalents, beginning of period | 2,694,663 | 2,039,853 | 437,604 | NaN |
| Cash and cash equivalents, end of period | 2,247,984 | 2,694,663 | 2,039,853 | NaN |